Engineered anti-IL-23P19 antibodies
View Patent ↗Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
1. A purified binding compound that binds to human IL-23, comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein:
CDRL1 comprises the sequence of SEQ ID NO: 36;
CDRL2 comprises the sequence of SEQ ID NO: 41; and
CDRL3 comprises the sequence of SEQ ID NO: 46; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein:
CDRH1 comprises the sequence of SEQ ID NO: 19;
CDRH2 comprises a sequence selected from the group consisting of SEQ ID NOs: 24-26; and
CDRH3 comprises the sequence of SEQ ID NO: 31.
2. The binding compound of claim 1 wherein CDRL2 comprises the sequence of SEQ ID NO: 24.
3. The binding compound of claim 1 wherein CDRL2 comprises the sequence of SEQ ID NO: 25.
4. The binding compound of claim 1 wherein CDRL2 comprises the sequence of SEQ ID NO: 26.
5. The binding compound of claim 2 comprising:
a) an antibody light chain variable domain comprising residues 1-108 of SEQ ID NO: 14; and
b) an antibody heavy chain variable domain comprising residues 1-116 of SEQ ID NO: 6.
6. The binding compound of claim 3 comprising:
a) an antibody light chain variable domain comprising residues 1-108 of SEQ ID NO: 14; and
b) an antibody heavy chain variable domain comprising residues 1-116 of SEQ ID NO: 7.
7. The binding compound of claim 4 comprising:
a) an antibody light chain variable domain comprising residues 1-108 of SEQ ID NO: 14; and
b) an antibody heavy chain variable domain comprising residues 1-116 of SEQ ID NO: 8.
8. The binding compound of claim 5 comprising an antibody light chain and an antibody heavy chain, wherein:
a) the antibody light chain comprises the sequence of SEQ ID NO: 14; and
b) the antibody heavy chain comprises the sequence of SEQ ID NO: 6.
9. The binding compound of claim 6 comprising an antibody light chain and an antibody heavy chain, wherein:
a) the antibody light chain comprises the sequence of SEQ ID NO: 14; and
b) the antibody heavy chain comprises the sequence of SEQ ID NO: 7.
10. The binding compound of claim 7 comprising an antibody light chain and an antibody heavy chain, wherein:
a) the antibody light chain comprises the sequence of SEQ ID NO: 14; and
b) the antibody heavy chain comprises the sequence of SEQ ID NO: 8.
11. The binding compound of claim 1 , further comprising a heavy chain constant region comprising a γ1 human heavy chain constant region.
12. The binding compound of claim 1 , further comprising a heavy chain constant region comprising a γ4 human heavy chain constant region.
13. The binding compound of claim 2 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
14. The binding compound of claim 3 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
15. The binding compound of claim 4 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 ,and a diabody.
16. The binding compound of claim 5 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
17. The binding compound of claim 6 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
18. The binding compound of claim 7 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
19. A pharmaceutical composition comprising the binding compound of claim 2 in combination with a pharmaceutically acceptable carrier or diluent.
20. A pharmaceutical composition comprising the binding compound of claim 3 in combination with a pharmaceutically acceptable carrier or diluent.
21. A pharmaceutical composition comprising the binding compound of claim 4 in combination with a pharmaceutically acceptable carrier or diluent.
22. A pharmaceutical composition comprising the binding compound of claim 5 in combination with a pharmaceutically acceptable carrier or diluent.
23. A pharmaceutical composition comprising the binding compound of claim 6 in combination with a pharmaceutically acceptable carrier or diluent.
24. A pharmaceutical composition comprising the binding compound of claim 7 in combination with a pharmaceutically acceptable carrier or diluent.
25. A pharmaceutical composition comprising the binding compound of claim 8 in combination with a pharmaceutically acceptable carrier or diluent.
26. A pharmaceutical composition comprising the binding compound of claim 9 in combination with a pharmaceutically acceptable carrier or diluent.
27. A pharmaceutical composition comprising the binding compound of claim 10 in combination with a pharmaceutically acceptable carrier or diluent.